Menú
Comité del programa
-
Julie Louise Gerberding • Chief Executive Officer
Foundation for the National Institutes of Health (FNIH), United States -
Tatsuya Kondo, MD, PhD • President
SH Medical Excellence JAPAN, Japan -
Teresa Ancukiewicz, MA • Associate Director
Boston Scientific Corporation, United States -
Jonathan Andrus, MS • Past Chair/Current Treasurer
Society For Clinical Data Management, United States -
Kimberly Belsky, MS • Reg Policy & Intell and AdPromo, Regulatory Affairs
Independent, United States -
Larry Blankstein, PhD • Head of Clinical Operations
Synlogic, United States -
Philip (P.J.) Brooks, PhD • Deputy Director, Division of Rare Diseases Research Innovation
National Center for Advancing Translational Sciences (NCATS), NIH, United States -
Jennifer Burgess, MBA, MPH • Vice President, Global Engagement and Communications
TransCelerate Biopharma Inc., United States -
Susan Callery-D'Amico, BSN • Retired, Vice President, R&D Quality Assurance, AbbVie
United States -
Juan Castano, MBA, PMP • Associate Director, Asset Planner
Pfizer Inc, United States -
Dannis Chang, PharmD • Director, Hematology Medical Information Team Lead
Genentech, Inc., United States -
Yeh-Fong Chen, PhD • Mathematical Statistician (Team Lead), Office of Translational Sciences, CDER
United States -
Karla Childers, MS • Head, Bioethics-Based Science and Technology Policy
Johnson & Johnson, United States -
Leah Christl, PhD • Exec Director, Global Biosimilars Regulatory Affairs & Regulatory & R&D Policy
Amgen, United States -
Deborah Collyar • President
Patient Advocates In Research (PAIR), United States -
Brenda Crowe, PhD • Associate Vice President, Statistics
Eli Lilly and Company, United States -
Sara Doshi, PharmD • Senior Director, Decentralized Clinical Trials
Eli Lilly and Company, United States -
Ron Fitzmartin, PhD, MBA • Senior Advisor, Office of Regulatory Operations, CBER
FDA, United States -
Barbara Gladson, PhD, MS • Director of Biopharma Initiative; Interim Chair, Health Informatics
Rutgers School of Health Professions, United States -
Richard Gliklich, MD • Chief Executive Officer
OM1, United States -
Jennifer Graff, PharmD • Senior Director, Professional Affairs
Academy of Managed Care Pharmacy (AMCP), United States -
William Gregory, PhD • Senior Director, Safety and Risk Management
Pfizer Inc, United States -
Marianne Hamilton Lopez, PhD, MPA • Research Director, Value-Based Payment Reform
Duke-Margolis Center For Health Policy, United States -
Sabine Haubenreisser, PhD, MSc • Principal Scientific Administrator, Stakeholders and Communication Division
European Medicines Agency, Netherlands -
Jennifer Helfer, PhD • Senior Director, Patient Advocacy and Engagement, Corporate Affairs
Viridian Therapeutics, Inc., United States -
Frank Hubbard, PhD, MS • President
Global Regulatory Writing Solutions Inc., United States -
Ginny Hussong • Branch Chief, Data Standards, CBER
FDA, United States -
Nita Ichhpurani, PMP • Consultant To Daiichi Sankyo, Inc.
Phase One Forward, Consultant, Canada -
Nadina Jose, MD • Assistant Professor, School of Health Professions, MS Clinical Research Program
Rutgers, The State University of New Jersey, United States -
Sean Kassim, PhD • Director, Office of Study Integrity and Surveillance, OTS, CDER
FDA, United States -
Sean D. Kennedy, MPH • Global Head, Real World Evidence
ICON plc, United States -
Agnes Klein, MD • Senior Medical Advisor
Health Canada, Canada -
Mark Kryah, PMP • Executive Director, Program Team Leader, Program and Portfolio Management
Ultragenyx Pharmaceutical Inc., United States -
Vicky Martin • Sr Director Business Development USA
IDDI, United States -
Chris Matheus, MBA • Chief Commercial and Networking Officer
Global Life Sciences Alliance (GLSA), United States -
Ann Meeker-O'Connell, MS • Director, Office of Clinical Policy, Office of Clinical Policy and Programs, OC
FDA, United States -
Christine Moore, PhD • Executive Director, Global External Advocacy and Standards
Organon & Co., United States -
Jean M. Mulinde, MD • Associate Director, Division of Clinical Compliance Evaluation, OSI
FDA, United States -
Michael Neidl, MBA, MS, MSc • Senior Consultant
Clinical Research Quality Consultant, United States -
Lisa Palladino-Kim, MS • Program Director / Lecturer
Rutgers School of Health Professions Clin Research Mgmt, United States -
David J Pepperl, PhD • Senior Consultant and Nonclinical Group Leader
Biologics Consulting, United States -
Kim Quaintance-Lunn • Vice President, Head of Regulatory Science and Execution
Alexion, United States -
Margaret Richards, PhD, MPH • Executive Director, Solutions
Panalgo, United States -
Peter Richardson, PhD • Head of Quality, Specialised Scientific Disciplines Department
European Medicines Agency, Netherlands -
Steven L. Roberds, PhD • Chief Scientific Officer
Tuberous Sclerosis Alliance, United States -
Khyati Roberts, RPh • Retired
Retired, United States -
Mitra Rocca, MSc • Associate Director, Medical Informatics, Office of Translational Science, CDER
FDA, United States -
David H. Schubert •
DH Schubert Regulatory Solutions LLC, United States -
Leigh Shultz, PhD, PMP • Executive Director, Human Health Commercial Operations
Merck & Co., Inc., United States -
Nancy Pire Smerkanich, DrSc, MS • Assistant Professor Regulatory & Quality Sciences
University of Southern California School of Pharmacy, United States -
Meredith Smith, PhD, MPA, FISPE • Senior Director, Implementation Science Pillar Lead
Evidera, Inc, United States -
Elizabeth Somers, MS • Executive Director, Global Project and Alliance Management
Merck Sharp & Dohme LLC, United States -
Jeffrey N. Stuart, PhD • Associate Vice President, Global Regulatory Affairs
Merck Sharp & Dohme LLC , United States -
Ling Su, PhD • Research Fellow
Shenyang Pharmaceutical University, Yeehong Business School, China -
Veronica Todaro, MPH • Chief Operating Officer
Parkinson's Foundation, United States -
Toshiyoshi Tominaga, PhD • Project Professor
Keio University Hospital, Japan -
Rebecca A. Vermeulen, RPh • Vice President, Global Patient Networks | PD Medical Affairs
Genentech, A Member of the Roche Group, United States -
Kristin Voorhees, MA • Director, Patient Advocacy
Ultragenyx, United States -
Karen D. Weiss, MD • Vice President, Global Regulatory Affairs
Janssen Pharmaceutical Companies of Johnson & Johnson, United States -
Robin Whitsell • President
Whitsell Innovations, Inc., United States -
Annette S. Williams, MBA, RPh • Vice President, Pharmacovigilance
IQVIA, United States -
Michael Williams • Managing Partner
Facio Consulting Group and Associates, United States -
Amy Xia, PhD • Vice President, Center for Design and Analysis
Amgen Inc., United States -
Judith Zander, MD • Director, Office of Pharmacovigilance and Epidemiology, OSE, CDER
FDA , United States